AEON Biopharma, Inc.
AEON · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $33 | $35 | $26 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $14 | $20 | $14 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$101 | $295 | $0 | $29 |
| Operating Expenses | -$73 | $348 | $48 | $66 |
| Operating Income | $73 | -$348 | -$48 | -$66 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$31 | -$37 | -$4 | $10 |
| Pre-Tax Income | $42 | -$385 | -$53 | -$56 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $42 | -$385 | -$53 | -$56 |
| % Margin | – | – | – | – |
| EPS | 77.74 | -4.99 | -27.25 | -31.73 |
| % Growth | 1,657.9% | 81.7% | 14.1% | – |
| EPS Diluted | 72.93 | -4.99 | -27.25 | -31.73 |
| Weighted Avg Shares Out | 1 | 77 | 2 | 2 |
| Weighted Avg Shares Out Dil | 1 | 77 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$28 | -$53 | -$48 | -$37 |
| % Margin | – | – | – | – |